| Vol. 25.13 – 15 April, 2024 |
| |
|
|
| Researchers showed that overexpression of FOXO1 promoted a stem-like phenotype in CAR T cells derived from either healthy human donors or patients, which correlated with improved mitochondrial fitness, persistence and therapeutic efficacy in vivo. [Nature] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Investigators reported that CTX130 showed favorable preclinical proliferation and cytotoxicity profiles and completely regressed renal cell carcinoma xenograft tumors. [Cancer Discovery] |
|
|
|
| The authors used a major histocompatibility complex-mismatched mouse model to follow the fate of in vitro expanded donor regulatory T cells upon migration to target organs [Nature Communications] |
|
|
|
| With a humanized NSG-SGM3 mouse model, scientists showed reduced CRS-related toxicity in mice treated with CAR-T cells secreting tocilizumab-derived single-chain variable fragment, yielding a safety profile superior to that of single-dose systemic tocilizumab administration. [Journal Of Experimental Medicine] |
|
|
|
| Investigators showed that the implantation of seven-stage induced PSC-derived pancreatic islet cells led to the emergence of unexpected off-target cells with proliferative capacity via in vivo maturation. [Proceedings Of The National Academy Of Sciences Of The United States Of America] |
|
|
|
| Researchers incorporated a short hairpin RNA cassette targeting PD-1 into a B cell maturation antigen-CAR with an OX-40 costimulatory domain. [Journal For Immunotherapy Of Cancer] |
|
|
|
| The authors conducted a Phase I clinical trial to investigate the application of autologous lymphocyte infusion and anti-SLAMF7 monoclonal antibody, elotuzumab, after autologous stem cell transplantation in patients with newly diagnosed multiple myeloma previously treated with induction therapy. [Journal For Immunotherapy Of Cancer] |
|
|
|
| While there were no pre-existing T cell features associated with clinical outcomes, scientists found that patients with a durable response to CAR-T cell treatment had greater persistence of their CAR-T cells compared to patients with transient clinical responses. [Blood Advances] |
|
|
|
|
Researchers assessed mature exogenous rataxin in humans (hFXN expression levels in the heart and liver of C57Bl/6 mice seven-ten months after intravenous administration of a recombinant adeno-associated virus encoding hFXN and examined the potential for hFXN truncation in mice. [Scientific Reports] |
| | |
|
|
| The authors outline the ex vivo manufacturing process as a motivating framework for direct in vivo strategies and discuss emerging data from preclinical models to highlight the potency of the in vivo approach [Trends In Pharmacological Sciences] |
|
|
|
| The utilization of genetically modified vectors enables in vivo production of CAR-T cells, thereby abbreviating or skipping the lengthy in vitro expansion process. [Cancer And Metastasis Reviews] |
|
|
|
|
| UFC, the world’s premier mixed martial arts organization, and Cellular Performance Institute (CPI), the world’s foremost advanced stem cell and regenerative medicine company, announced a new global marketing partnership that will showcase CPI branding within some of UFC’s biggest events. [UFC] |
|
|
|
|
Five scientists walked into a lab late last year and decided to establish a startup combining their wide-ranging expertise, practical experience and breakthrough innovations. The goal of their startup, Somite.ai, is to improve the lives of millions of people by leveraging AI to produce human tissue for cell therapies. [Forbes] |
| |
|
|
| May 20, 2024 New York, New York, United States & Online |
|
|
|
|
|
| University of Oregon – Eugene, Oregon, United States |
|
|
|
| University of Wisconsin-Madison – Madison, Wisconsin, United States |
|
|
|
| Monash University – Melbourne, Victoria, Australia |
|
|
|
| Virginia Commonwealth University – Richmond, Virginia, United States |
|
|
|
| New York University Abu Dhabi – Abu Dhabi, United Arab Emirates |
|
|
|
|